Clinical trials: Recurrence Hepatocellular Carcinoma
Hepatocellular Carcinoma, Microwave Ablation
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
- Conditions
- Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
- Trial name
- NCT06609876
- Testing
- Thermal ablation, Donafenib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Recurrence of Hepatocellular Carcinoma
analysis of the risk factors of intra-hepatic distant recurrence (IDR) of hepatocellular carcinoma within 1 year after radiofrequency ablation.
- Trial name
- NCT01520779
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Ain Shams University
Hepatocellular Carcinoma (HCC)
Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment
This study plans to enroll 704 patients with a history of chronic hepatitis B who have undergone radical treatment for hepatocellular carcinoma.
- Trial name
- BRCSRRRHCCART (NCT06923176)
- Testing
- Biejia-Ruangan compound, Routine medical care
- Volunteers
- 704 people
- Sponsor
- Zhiyun Yang
Hepatocarcinoma
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation
- Trial name
- NCT03356236
- Where
- 17 sites in China
- Volunteers
- 828 people
- Sponsor
- Yue Han
Liver Cancer
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
RATIONALE: Sorafenib tosylate and pravastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01075555
- Testing
- pravastatin sodium, sorafenib tosylate
- Where
- France
- Volunteers
- 323 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue in patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01194206
- Testing
- stereotactic body radiation therapy
- Sponsor
- Case Comprehensive Cancer Center
Resectable Hepatocellular Carcinoma
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
- Trial name
- NCT04834986
- Testing
- Tislelizumab combined with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Neoplasm Metastasis
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.
- Trial name
- NCT00561522
- Testing
- Capecitabine, No other preventive treatment
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Fudan University
RFS
Single-Arm Clinical Study of Icaritin Soft Capsules as Adjuvant Therapy for Hepatocellular Carcinoma Patients at High Risk of Postoperative Recurrence
Observing the Efficacy and Safety of Icaritin Soft Capsules as Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Patients with High-Risk Factors for Recurrence (A Single-Arm, Single-Center, Prospective Clinical Study…
- Trial name
- NCT07328828
- Testing
- Icaritin soft capsules
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
Lenvatinib is an oral multi-target receptor tyrosine kinase inhibitor (TKI) inhibitor that mainly inhibits the Endothelial growth factor receptor (VEGFR) VEGFR-1,2,3; Fibroblast growth factor receptor, FGFR) FGFR-1,2,3,4…
- Trial name
- NCT05803928
- Testing
- lenvatinib + anti-PD-1 antibodies, ablation
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Hua Li
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma, TACE
Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence
A single-arm, open-label clinical trial to assess the effects and safety of anlotinib hydrochloride combined with transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma(HCC) patients at high risk of post…
- Conditions
- Hepatocellular Carcinoma, TACE, Anlotinib
- Trial name
- ALTER-H-004 (NCT04213118)
- Testing
- Anlotinib Hydrochloride, TACE
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatocellular Carcinoma, Hepatitis C
HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals (DAAs) given for hepatitis C virus treatment are contradictory.
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Neoplasm Recurrence, Treatment Complication
- Trial name
- RCT (NCT04653818)
- Testing
- Velpatasvir/Sofosbuvir
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Alexandria University
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
CT Scans Prior to Surgery With a Least 2 Years of Follow-up
Identification of Image Phenotypes to Predict Recurrence After Resection of Hepatocellular Carcinoma
Tumor recurrence, which occurs in 70% of patients with HCC within 5 years after hepatic resection, is a major cause of post-resection-death.
- Trial name
- LIVERIBIOPSY (NCT05235490)
- Testing
- Non intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HCC
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
Radiofrequency ablation (RFA)can be curative with small localized HCCs up to 5 cm in diameter. However, the long-term prognosis is not satisfactory due to the high incidence of recurrence.Multimodality treatments are needed to…
- Trial name
- NCT02187081
- Testing
- radiofrequency ablation plus Sorafenib, Radiofrequency ablation
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Southwest Hospital, China
Recurrent Small Hepatocellular Carcinoma, Residual Small Hepatocellular Carcinoma
Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC
This phase 3 study is to evaluate the effectiveness of the comparison between radiofrequency ablation and hypofractionated proton beam radiation.
- Trial name
- NCT01963429
- Testing
- radiofrequency ablation, Proton beam therapy
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- National Cancer Center, Korea
Liver Cancer
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00335829
- Testing
- bevacizumab, chemotherapy, embolization therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Yale University
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have…
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor
- Trial name
- NCT00019630
- Testing
- doxorubicin HCl liposome
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center